Beryl A. Koblin|Patrick J. Heagerty|Amy R. Sheon|Susan Buchbinder|Connie Celum|John M. Douglas|Michael L. Gross|Michael Marmor|Kenneth H. Mayer|David Metzger|George R. Seage
Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States
New York Blood Center|Fred Hutch Cancer Center|Westat (United States)|National Institute of Allergy and Infectious Diseases|National Institutes of Health|San Francisco Department of Public Health|University of Washington|Denver Public Health|Abt Associates (United States)|Columbia University Irving Medical Center|New York University|Fenway Health|University of Pennsylvania|Boston University|Abt Associates (United States)
determine willingness populations high risk hiv1 infection participate hiv vaccine efficacy trials determine factors influencing decisionmaking evaluate knowledge levels vaccine trial conceptscrosssectional studyhiv1negative homosexual men male female injecting drug users noninjecting women heterosexual risk recruited eight cities united states n4892a substantial proportion study population 77 would definitely 27 probably 50 willing participate randomized vaccine efficacy trial increased willingness associated highrisk behaviors lower education level uninsured covered public insurance previous vaccine preparedness study altruism desire protection vaccine major motivators participation major concerns included positive hiv1 antibody test due vaccine safety vaccine possible problems insurance foreign travel baseline knowledge vaccine trial concepts lowit likely highrisk volunteers willing enroll hiv vaccine efficacy trials variety participant community educational strategies needed address participant concerns ensure understanding key concepts prior giving consent participation